Silexion Therapeutics announces new findings from Loder trial

Silexion Therapeutics announced new findings from its Phase 2 trial of Loder in patients with non-resectable locally advanced pancreatic cancer, or LAPC, which bear the KRAS G12D or G12V mutation. Overall the updated analysis reveals a 56% objective response rate, or ORR, in patients treated with Loder, with the ORR increasing to 67% in patients whose previously non-resectable tumors became resectable. This marks a significant step forward in potentially improving surgical outcomes for LAPC patients. Silexion had previously reported that patients treated with Loder in combination with standard-of-care, or SoC, chemotherapy experienced a 9.3-month improvement in overall survival, or OS, compared to chemotherapy alone. The new data now underscores LODERs additional potential to increase the resectability of tumors, opening up more surgical options for patients with otherwise inoperable pancreatic cancer. Silexion is also progressing with the development of its next generation product, SIL-204, which builds upon the efficacy of the Loder. SIL-204 is designed to target a broader range of KRAS mutations, covering pan- G12x and G13D, as well as the previously reported findings of properties which should make it more effective clinically such as improved stability and enhanced ability to get to the site of action for silencing the KRAS oncogene. These improved properties demonstrated in preclinical models position SIL-204 as a promising option for the treatment of difficult-to-treat cancers such as locally advanced pancreatic cancer. Silexion continues to proceed with the development of this optimized candidate.